Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Here’s What Happened

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) gapped up before the market opened on Friday . The stock had previously closed at $4.70, but opened at $4.95. Autolus Therapeutics shares last traded at $4.68, with a volume of 58,237 shares.

Autolus Therapeutics Price Performance

The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. The business’s fifty day moving average is $3.94 and its 200 day moving average is $4.13. The company has a market cap of $1.28 billion, a P/E ratio of -4.00 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, sell-side analysts anticipate that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in shares of Autolus Therapeutics by 253.5% in the second quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock valued at $3,985,000 after purchasing an additional 821,156 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after buying an additional 2,487,778 shares in the last quarter. Millennium Management LLC raised its holdings in Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock valued at $2,829,000 after acquiring an additional 432,503 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Autolus Therapeutics by 2,603.8% during the first quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock worth $736,000 after acquiring an additional 111,131 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Autolus Therapeutics by 27.4% in the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after acquiring an additional 925,000 shares during the period. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.